Polytabletka + aspirin

The use of combined tablets and aspirin reduces the risk of heart disease

Anna Yudina, "Scientific Russia"

One tablet for daily intake, combining medications for blood pressure and cholesterol, as well as the addition of a daily dose of aspirin, reduced the incidence of cardiovascular diseases in people at risk of heart disease, - reports the press release of the American Heart Association New study confirms combo pill alone and with aspirin lowers heart disease risk.

This conclusion was made during the latest studies presented today in the latest presentation of clinical trials at the scientific sessions of the American Heart Association 2020.

The medicine tested in this study is a combination therapy with fixed doses, combining medications that lower blood pressure and cholesterol. The researchers evaluated the effect of such a polytablet on cardiovascular diseases, such as heart attack, stroke and death from cardiovascular diseases, when used alone or with aspirin in patients belonging to the group of average risk of cardiovascular diseases. They also investigated the effects of aspirin alone.

The Polycap International Trial (TIPS) -3 is a large randomized placebo-controlled trial conducted in nine countries. The study included 5,700 people belonging to the group of average risk of developing heart disease. The average age of the participants was 64 years, of which 47% were men.

Participants were randomly assigned to various interventions: 1) 75 mg of aspirin per day; 2) a polytablet combining medication for high blood pressure and cholesterol daily; 3) a polytablet and aspirin 75 mg per day; or 4) vitamin D 5000 IU per day. Each intervention included a control group that received an appropriate placebo. Medications in the polytablet: atenolol 100 mg, ramipril 10 mg, hydrochlorothiazide 25 mg and simvastatin 40 mg.

Over a nearly five-year follow-up period, participants were monitored for the first occurrence of a serious cardiovascular event, such as a nonfatal heart attack, nonfatal stroke, heart failure, resuscitation cardiac arrest, or cardiovascular death.

The analysis of all groups of patients revealed:

one polytablet reduced the likelihood of cardiovascular diseases by 21%;
aspirin alone reduced mortality from cardiovascular diseases, heart attack or stroke by 14%;
polytablet plus aspirin reduced the risk of cardiovascular diseases by 31%.

"Aspirin should be prescribed together with polytablets as primary prevention for patients at intermediate risk of heart disease," said Salim Yusuf, MD, PhD, co–author of the study and professor of medicine at McMaster University School of Medicine. Medicine in Toronto (Canada). "The results of our study provide important data on the role of the polytablet in preventing the development of heart disease."

Co-author Prem Pais, MD, Professor of the Department of Clinical Research and Training at the St. Petersburg Research Institute. John in Bangalore (India), added: "We were also interested in evaluating the possibility of combining drugs to reduce blood pressure and cholesterol in one tablet and the effectiveness of such a pill for this population group. This is a cost-effective strategy that can help achieve global goals to reduce cardiovascular disease by 30% by 2030."

"Using a polytablet in combination with aspirin can prevent 3-5 million deaths from cardiovascular diseases worldwide," Yusuf said. "Future polytablets with new statins can reduce LDL cholesterol and blood pressure to a greater extent, and can also reduce the risk of cardiovascular diseases by more than 50%."

Portal "Eternal youth" http://vechnayamolodost.ru